LB 03002 success in treatment of Growth Hormone Deficiency

Phase III results were announced of 24 months efficacy and safety in children with Growth Hormone Deficiency (GHD) for LB 03002, a once-a-week, sustained release recombinant human growth hormone (hGH) from Biopartners and LG Life Sciences (LGLS), at the annual meeting of the European Society for Paediatric Endocrinology. The study involved 167 paediatric patients with GHD. The data demonstrate that LB03002, using LGLS' delivery technology Biohydrix, maintained expected growth rates for patients continuously treated for 24 months as well as in patients treated for 12 months who were switched from daily therapy, according to the companies. IGF-1 levels continued to increase toward the normal range in both groups during LB 03002 treatment, a key marker of efficacy and safety in growth hormone therapy. LB 03002 was well tolerated and demonstrated a sustained growth potential without excessive bone maturation. LB03002 was originally developed by LGLS who granted Biopartners a licence to further develop and market the product in Europe, Australia, New-Zealand and several other countries. LGLS retains rights in the rest of the world including North and South America, and most Asian countries including Korea, Japan, and China.